Overall rank by patents
#28,697
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Encore Medical Asset Corporation
USPTO PatentsView assignee record - 9 granted patents across 1 technology areas, active 2015–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).
9
Total patents granted
1
CPC technology areas
24.7
Avg claims per patent
-87%
5-year filing velocity
The verdict
Encore holds 9 US patents across 1 technology areas, rank #28,697 of 50,000 tracked assignees.
- #28,697
- of 50,000 US assignees by volume
- Top 57%
- by Innovation Score (33.0/100)
- 24.7
- avg claims per patent
- -87%
- filing velocity, last 5 yrs
Portfolio overview
Encore Medical Asset Corporation has been granted 9 US utility patents between 2015 and 2023, placing Encore Medical Asset Corporation at rank #28,697 across all assignees tracked by PlainPatent. This portfolio spans 1 distinct Cooperative Patent Classification (CPC) subclasses, averaging 24.7 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a US Corporation, Encore Medical Asset Corporation is one of the more focused assignees in the PatentsView dataset. By volume, Encore sits between Emery Oleochemicals Gmbh (9 patents, rank #28,693) and Ensitech IP Pty. Limited (9 patents, rank #28,701) - the closest US assignees by grant volume. The composite Innovation Score of 33.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 1 grants, compared with 8 in the 2015–2019 window, a -87% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Encore Medical Asset Corporation's 24.7 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 1 subclass reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Encore Medical Asset Corporation against peers pursuing similar technology classes.
Who files at Encore's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Emery Oleochemica…
Emery Oleochemicals GmbH
9 patents
- Empow Cyber Secur…
Empow Cyber Security Ltd.
9 patents
- Ene Holdings
EnE Holdings Ltd
9 patents
- Encompass Vascular
Encompass Vascular, Inc.
9 patents
- Endovision Founda…
Endovision Foundation
9 patents
- Endura SPA
Endura SPA
9 patents
- Enevo Oy
Enevo Oy
9 patents
- Ensitech IP Pty
Ensitech IP Pty. Limited
9 patents
- Encore Medical As… ◀
Encore Medical Asset Corporation
9 patents
What this shows Encore holds 9 patents at rank #28,697, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Encore
By rank, the assignees closest to #28,697 in granted patent volume.
- Emery Oleochemicals Gmbh #28,693 · 9 patents
- Empow Cyber Security Ltd. #28,694 · 9 patents
- Ene Holdings Ltd #28,695 · 9 patents
- Encompass Vascular, Inc. #28,696 · 9 patents
- Endovision Foundation #28,698 · 9 patents
- Endura SPA #28,699 · 9 patents
- Enevo Oy #28,700 · 9 patents
- Ensitech IP Pty. Limited #28,701 · 9 patents
Leaders in A61N (Electrotherapy)
Other assignees with the most granted patents in Encore's primary technology class.
- Medtronic, Inc. 2,200 in class
- Boston Scientific Neuromodulation Corporation 1,080 in class
- Cardiac Pacemakers, Inc. 1,037 in class
- Pacesetter, Inc. 609 in class
- ZOLL Medical Corporation 556 in class
- Koniniklijke Philips N.v. 534 in class
- Cochlear Limited 449 in class
- Varian Medical Systems, Inc. 296 in class
Encore's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
33 Top 57% higher than 43% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 22.2% |
| 2016 | 2 | 22.2% |
| 2017 | 3 | 33.3% |
| 2019 | 1 | 11.1% |
| 2023 | 1 | 11.1% |
Which technologies does Encore Medical Asset Corporation patent most?
Top 1 of 1 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Velocity Declining
Frequently Asked Questions
How many patents does Encore Medical Asset Corporation hold?
Encore Medical Asset Corporation holds 9 US granted patents filed between 2015 and 2023, spanning 1 technology areas.
What is Encore Medical Asset Corporation's Innovation Score?
Encore Medical Asset Corporation has an Innovation Score of 33.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Encore Medical Asset Corporation focus on?
Encore Medical Asset Corporation's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 9 patents. The company has filed patents in 1 CPC subclasses total.
Is Encore Medical Asset Corporation's patent filing rate increasing or decreasing?
Encore Medical Asset Corporation's recent filing velocity is -87% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Encore Medical Asset Corporation's patents?
Encore Medical Asset Corporation's patents average 24.7 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Encore Medical Asset Corporation patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Encore's 9 grants land it in the top 57% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Encore ranks #28,697 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61N - see who else leads that technology area. A61N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.